No connection

Search Results

BDRX vs INM

BDRX
Biodexa Pharmaceuticals Plc
BEARISH
Price
$2.15
Market Cap
$1.8M
Sector
Healthcare
AI Confidence
95%
INM
InMed Pharmaceuticals Inc.
BEARISH
Price
$0.72
Market Cap
$2.4M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
BDRX
--
INM
--
Forward P/E
BDRX
--
INM
-0.11
P/B Ratio
BDRX
0.09
INM
0.21
P/S Ratio
BDRX
--
INM
0.53
EV/EBITDA
BDRX
-15012.8
INM
0.57

Profitability

Gross Margin
BDRX
0.0%
INM
29.73%
Operating Margin
BDRX
0.0%
INM
-258.57%
Profit Margin
BDRX
0.0%
INM
-170.07%
ROE
BDRX
-61.77%
INM
-97.2%
ROA
BDRX
-39.04%
INM
-49.77%

Growth

Revenue Growth
BDRX
--
INM
-26.2%
Earnings Growth
BDRX
--
INM
--

Financial Health

Debt/Equity
BDRX
0.04
INM
0.06
Current Ratio
BDRX
3.63
INM
5.94
Quick Ratio
BDRX
3.63
INM
4.85

Dividends

Dividend Yield
BDRX
--
INM
--
Payout Ratio
BDRX
0.0%
INM
0.0%

AI Verdict

BDRX BEARISH

The Advanced Deterministic Scorecard reveals a critically weak financial profile with a Piotroski F-Score of 2/9, indicating severe operational and financial distress. Despite a strong current and quick ratio suggesting short-term liquidity, the company is unprofitable across all margins, with deeply negative ROE and ROA. Valuation metrics are largely undefined due to lack of earnings and revenue data, while the stock has lost nearly all value over the past year. Insider sentiment is neutral-to-weak, and there is no analyst coverage or dividend support, amplifying risk.

Strengths
Strong liquidity position with current and quick ratios of 3.63, indicating ability to cover short-term liabilities.
Low debt/equity ratio of 0.04, reflecting minimal leverage risk.
Two out of three recent quarters beat earnings estimates, showing some operational predictability.
Risks
Piotroski F-Score of 2/9 indicates very weak financial health and high risk of continued deterioration.
No Altman Z-Score available, but negative ROE (-61.77%) and ROA (-39.04%) suggest high bankruptcy risk.
Profitability metrics are entirely negative: 0% gross, operating, and profit margins.
INM BEARISH

The company exhibits critical financial distress, highlighted by a Piotroski F-Score of 1/9, indicating severe weakness across nearly all fundamental health dimensions. While the current ratio is high (5.94), this is offset by a catastrophic profit margin of -170.07% and declining year-over-year revenue growth of -26.20%. The stock is in a clear long-term death spiral, with a 5-year price change of -100% and a technical trend score of 0/100. Without a pivot to profitability or a significant capital infusion, the business model appears unsustainable.

Strengths
Very low Debt/Equity ratio (0.06) indicating minimal long-term debt burden
Strong short-term liquidity with a Current Ratio of 5.94
Positive Gross Margin (29.73%) suggesting the core product has some inherent value
Risks
Critical financial health as evidenced by a 1/9 Piotroski F-Score
Severe operational inefficiency with an Operating Margin of -258.57%
Negative revenue growth (-26.20% YoY) indicating shrinking market share or demand

Compare Another Pair

BDRX vs INM: Head-to-Head Comparison

This page compares Biodexa Pharmaceuticals Plc (BDRX) and InMed Pharmaceuticals Inc. (INM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile